Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3510
-0.0080 (-2.22%)
Oct 7, 2025, 4:00 PM EDT - Market closed
Vaxart Revenue
Vaxart had revenue of $39.73M in the quarter ending June 30, 2025, with 520.68% growth. This brings the company's revenue in the last twelve months to $80.72M, up 479.58% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
$80.72M
Revenue Growth
+479.58%
P/S Ratio
1.01
Revenue / Employee
$768,800
Employees
105
Market Cap
80.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VXRT News
- 20 days ago - Vaxart Appoints W. Mark Watson as Lead Independent Director - GlobeNewsWire
- 27 days ago - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire
- 27 days ago - Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting - GlobeNewsWire
- 4 weeks ago - Vaxart Announces Adjournment of Special Meeting of Stockholders - GlobeNewsWire
- 5 weeks ago - Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. - GlobeNewsWire
- 5 weeks ago - Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability - GlobeNewsWire
- 6 weeks ago - Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights - GlobeNewsWire
- 7 weeks ago - Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript - Seeking Alpha